Clinical Rhabdomyolysis With Acute Kidney Injury Secondary to High-Intensity Rosuvastatin Use: A Case Report.

Autor: Chitralli D; Nephrology, Columbia Asia Referral Hospitals Yeshwanthpur, Bengaluru, IND., Raheja R; Internal Medicine, Columbia Asia Referral Hospital Yeshwanthpur, Bengaluru, IND., Br K; Internal Medicine, Columbia Asia Referral Hospital Yeshwanthpur, Bengaluru, IND.
Jazyk: angličtina
Zdroj: Cureus [Cureus] 2020 Oct 13; Vol. 12 (10), pp. e10932. Date of Electronic Publication: 2020 Oct 13.
DOI: 10.7759/cureus.10932
Abstrakt: Statins are the primary class of medication used to lower serum cholesterol concentration for both primary and secondary prevention of cardiovascular disease. Muscle pain is a frequent adverse effect of statins. Severe myonecrosis leading to clinical rhabdomyolysis is rare. We encountered a 63-year-old male with a medical history of hypertension, type 2 diabetes mellitus, and coronary artery disease with angioplasty in 2008 and 2020. He was started on rosuvastatin 40 mg (0-0-1) along with dual anti-platelets post angioplasty and was discharged home. He traveled back to his hometown and noticed progressive symmetric muscle weakness with decreased urine output. After visiting another hospital he presented to us with severe proximal muscle weakness and acute renal failure. Laboratory investigations were initiated which demonstrated clinically significant derangement in serum creatinine phosphokinase, serum creatinine, urine myoglobin along with deranged liver enzymes. He was subjected to nerve conduction studies for his muscle weakness which was normal and electromyography showed abnormal spontaneous muscle activity in all examined muscles (fibrillations, positive sharp waves, and pseudomyotonic discharges) suggestive of an irritable myopathy. The medication was stopped and he was treated with eight cycles of hemodialysis until his muscle weakness and laboratory parameters improved. He was then discharged with some improvement in muscle weakness. On two week follow-up, the patient showed partial improvement after discontinuation of all lipid-lowering medication.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2020, Chitralli et al.)
Databáze: MEDLINE